About Alpha BioAdvisors™

Valuation, Value Capture & Timing

Alpha BioAdvisors integrates over a decade of fundamental research experience (BioTrend Corp & Cantor Fitzgerald) with over a decade of quantitative research innovation to provide a distillation of these perspectives on the biotech segment. We developed a systematic methodology and created an alpha-capture-focused coverage universe selecting emerging technology biotech companies for institutional investors (Strategy Signal/IRC Securities). This translated into a massive effort to develop the first comprehensive quantitative model to analyze and forecast emerging technology biotech companies using 95 factors and 8 key characteristics viewed through the lens of three critical drivers of value (QuantSigns).

With a background of recognizing core value in biotech at early stages (see our library of independent institution-only equity research beginning 2012), Alpha BioAdvisorsTM understands how biotech companies unlock pivotal opportunities that can culminate in realized and recognized value creation. At the heart of every strategy and every transaction is valuation. Alpha BioAdvisors’ expertise in valuations of intellectual property/patents, programs, products, pipelines and companies are the foundation of our research. Using proprietary methodologies to examine and evaluate companies, we examine perceived value, recognized value and real asset value to reconcile disconnects with share price/market cap.

Alpha BioAdvisorsTM is Focused on Biotech Value

Sign Up Now

Now, with this foundation of 25+ years of biotech and pharm research/publication and strategic advisory including M&A and technology/product licensing to major pharmas, we are covering biotech via IBB Edit, analyzing the IBB ETF viewed through its key components and macro factors impacting valuation in biotech and via Valuation View that examines the drivers of biotech valuation.

A career start treating patients with Duchenne muscular dystrophy and other rare diseases led to pursuing a focus on biotech.

Pamela Bassett, DMD,MBA founder Alpha BioAdvisors 2023. Alpha-capture-focused biotech equity analyst, independent director, strategic advisor and entrepreneur. Over 25 years of experience providing research and consulting. Previous founding roles at QuantSigns, Strategy Signal/IRC, Cantor Fitzgerald. M&A strategic advisor to major pharmas, led a $2.2 B pharma product deal team, founded/built/merged first-in-class med tech company.

MBA Wharton, DMD Tufts, Anesthesiology Drexel Medicine, Certified Director UCLA, Certified Patent Valuation Analyst CPVA

Selected Technology Universe

  • RNA Interference (RNAi)
  • mRNA
  • Antisense
  • Monoclonal Antibodies (mAbs)
  • Cell Therapy
  • Gene Therapy
  • Crispr
  • Lipid Nanoparticles (LNPs)
  • Lipids & Liposomes
  • PEG
  • rDNA
  • Proteins
  • Peptides
  • Viral Vectors
  • Small Molecules
  • Controlled/Sustained Release

Valuation, Value Capture & Timing